The Official Journal entry can be found here (page 79).
- Huvepharma® has launched a new anticoccidial in Europe: Monimax®
- Monimax® is a microgranulated product combining monensin and nicarbazin
- Monimax® is registered for use in turkeys, broilers and laying hens
Coccidiosis remains a major concern for the poultry industry. Efficient coccidiosis control is paramount to safeguarding good performance. Suboptimal control of coccidiosis will decrease performance and, at the same time, may drive an increased use of antimicrobials for the treatment of intestinal problems for which coccidiosis is a trigger (dysbacteriosis, necrotic enteritis).
Monimax® is now registered for use in chickens for fattening, turkeys for fattening and chickens reared for laying in Europe. The synergy between monensin and nicarbazin allows the use of monensin and nicarbazin at lower concentrations (Vereechen et al., 2020), making it suitable for use in all conditions, all year round.
Monimax® has proven efficacy against all Eimeria species in chickens and turkeys. This new combination of monensin and nicarbazin will result in a synergistic effect against the current field species of Eimeria and data supports an improvement in poultry performance. Monimax® is registered and safe for use in turkeys and chickens, which makes the product convenient for use in feed mills producing feed for different poultry species. In addition, Monimax® improves bird welfare as good coccidiosis control will also improve litter quality which has a direct effect on foot pad lesions, an important welfare indicator.
